Intercept Pharma (ICPT) Posts Narrwer-than-Expected Q3 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts ICPT Hot Sheet
Join SI Premium – FREE
Intercept Pharma (NASDAQ: ICPT) reported Q3 EPS of ($2.10), $0.65 better than the analyst estimate of ($2.75). Revenue for the quarter came in at $445 thousand versus the consensus estimate of $420 thousand.
As of September 30, 2015, Intercept had cash, cash equivalents and investment securities available for sale of approximately $695.7 million, compared to $732.2 million as of June 30, 2015.
For earnings history and earnings-related data on Intercept Pharma (ICPT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Evercose ISI downgrades Reddit, says monetization may not offset traffic weakness
- Goldman Sachs Revises China Jewelry Stocks Amid Gold Price Retreat
- Freedom Broker Downgrades RPC Inc. (RES) to Sell
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
